Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Eszopiclone for insomnia.

Sarah T Melton1, Jill M Wood, Cynthia K Kirkwood

  • 1Patient Assistance Program, C-Health, P.C., Lebanon, VA, USA.

The Annals of Pharmacotherapy
|September 1, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Comparing four methods for assessing interprofessional learning in a practice setting.

Journal of interprofessional care·2025
Same author

Perceptions and Practices for Evaluating Faculty Workload by Pharmacy Education Administration/Leadership.

American journal of pharmaceutical education·2023
Same author

Esketamine: A Novel Option for Treatment-Resistant Depression.

The Annals of pharmacotherapy·2019
Same author

Identifying clinical net benefit of psychotropic medication use with latent variable techniques: Evidence from Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD).

Journal of affective disorders·2018
Same author

Point/Counterpoint: Are Outstanding Leaders Born or Made?

American journal of pharmaceutical education·2017
Same author

Prevalence of Antidiabetic and Antilipidemic Medications in Children and Adolescents Treated With Atypical Antipsychotics in a Virginia Medicaid Population.

The Annals of pharmacotherapy·2016
Same journal

Prolonged Response to Nivolumab in Metastatic Vulvar Carcinoma: Should Immunotherapy be Continued and for How Long? A Debatable Issue!

The Annals of pharmacotherapy·2026
Same journal

Stability of Ceftazidime-Avibactam: Changes in Regulatory Information and Implications for Preparation.

The Annals of pharmacotherapy·2026
Same journal

Impact of Early Dose Adjustment of Piperacillin/Tazobactam on Mortality in Critically Ill Patients With Acute Kidney Injury: A Retrospective Multicenter Cohort Study.

The Annals of pharmacotherapy·2026
Same journal

Severe Phototoxic Skin Reaction Associated With Vandetanib: Implications for Pharmaceutical Care.

The Annals of pharmacotherapy·2026
Same journal

Efficacy and Safety of Oral PCSK9 Inhibitors in Adults With Hypercholesterolemia: An Updated Systematic Review and Meta-Analysis of RCTs.

The Annals of pharmacotherapy·2026
Same journal

RSVpreF: A Vaccine for the Respiratory Syncytial Virus.

The Annals of pharmacotherapy·2026
See all related articles

Eszopiclone effectively treats transient and chronic insomnia in adults and the elderly. Studies show it is safe and well-tolerated, with no observed tolerance or rebound insomnia during long-term use.

Area of Science:

  • Pharmacology and Sleep Medicine

Background:

  • Insomnia is a prevalent sleep disorder affecting adult and geriatric populations.
  • Pharmacological interventions are crucial for managing transient and chronic insomnia.

Purpose of the Study:

  • To comprehensively review the pharmacology, pharmacokinetics, efficacy, and safety of eszopiclone.
  • To evaluate eszopiclone's utility in treating insomnia in adult and elderly patients.

Main Methods:

  • A MEDLINE literature search (1966-May 2005) identified relevant studies.
  • Included were 5 double-blind, placebo-controlled trials and 1 open-label extension trial.
  • Data from the drug manufacturer supplemented the literature review.

Main Results:

  • Eszopiclone demonstrated statistically significant improvements in sleep parameters across all reviewed studies.

Related Experiment Videos

  • The drug was found to be safe and effective for both transient and chronic insomnia.
  • No tolerance or rebound insomnia was observed during a 6-month open-label trial.

    • Conclusions:

    • Eszopiclone is a safe and effective treatment option for insomnia in adult and geriatric patients.
    • Sustained sleep parameter improvements were noted with long-term eszopiclone use.
    • Further comparative studies with other non-benzodiazepine hypnotics, including cost-effectiveness, are warranted.